← Back to Screener
MetaVia Inc. Common Stock (MTVA)
Price$2.57
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-77.90%
Price vs S&P 500 (4W)135.79%
VGM Score38.56
Market Capitalization$13.27M
All Metrics
Book Value / Share (Quarterly)$1.76
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.93
Price vs S&P 500 (YTD)-77.64%
EPS (TTM)$-6.03
10-Day Avg Trading Volume6.97M
EPS Excl Extra (TTM)$-6.03
EPS (Annual)$-7.35
ROI (Annual)-243.26%
Cash / Share (Quarterly)$2.66
ROA (Last FY)-116.63%
EBITD / Share (TTM)$-5.14
ROE (5Y Avg)-166.96%
Cash Flow / Share (Annual)$-6.80
P/B Ratio1.46x
P/B Ratio (Quarterly)0.67x
Net Income / Employee (Annual)$-1,621,600
Net Interest Coverage (TTM)-5.38x
ROA (TTM)-89.38%
EPS Incl Extra (Annual)$-7.35
Current Ratio (Annual)1.93x
Quick Ratio (Quarterly)2.71x
3-Month Avg Trading Volume2.64M
52-Week Price Return-66.14%
Revenue / Employee (TTM)$0
52-Week High$19.03
EPS Excl Extra (Annual)$-7.35
CapEx CAGR (5Y)-47.98%
26-Week Price Return-69.98%
Quick Ratio (Annual)1.92x
13-Week Price Return61.64%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.73x
Enterprise Value$-458,600
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.45
3-Month Return Std Dev215.06%
Net Income / Employee (TTM)$-1,640,600
ROE (Last FY)-243.26%
Net Interest Coverage (Annual)-1.14x
EPS Basic Excl Extra (Annual)$-7.35
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-6.03
ROI (TTM)-172.92%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-90.51%
Year-to-Date Return-69.48%
5-Day Price Return-5.86%
EPS Normalized (Annual)$-7.35
ROA (5Y Avg)-94.73%
Month-to-Date Return-9.51%
EBITD / Share (Annual)$-7.75
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-166.96%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-6.03
P/B Ratio (Annual)3.63x
Book Value / Share (Annual)$2.31
Price vs S&P 500 (13W)53.38%
Beta0.86x
Revenue / Share (TTM)$0.00
ROE (TTM)-172.92%
52-Week Low$0.97
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.79est. -0.76
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.22
4.22
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MTVAMetaVia Inc. Common Stock | — | — | D | $2.57 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
MetaVia Inc is a clinical-stage biotechnology company developing therapeutics for cardiometabolic diseases, with focus areas in metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company's pipeline includes DA-1241, a GPR119 agonist targeting MASH and Type 2 Diabetes, and DA-1726, a GLP-1/glucagon receptor dual agonist designed for once-weekly administration in obesity treatment.